繁體中文
返回
- English
- 繁體中文
- 简体中文
- 深色
- 淺色
立即開戶
Illumina | 10-K: FY2023 Annual Report
Illumina | 10-K: FY2023 Annual Report
Illumina | 10-K:2023財年年報
牛牛AI助理已提取核心訊息
Illumina, a global leader in DNA sequencing and array-based technologies, has reported a 2% decrease in revenue for the fiscal year 2023, amounting to $4.5 billion compared to $4.6 billion in the previous year. The decline was attributed primarily to reduced sales in sequencing consumables and instruments, though partially offset by increased service and other revenue. Gross profit margin also fell to 60.9% from 64.8% in 2022, influenced by lower fixed cost leverage and reduced instrument margins following the NovaSeq X launch. Operating loss improved to $(1.1) billion in 2023 from $(4.2) billion in 2022, with a significant reduction in operating expenses, including a decrease in goodwill and intangible impairment charges. The company's effective tax rate was (3.9)% in 2023. Illumina's business development has been marked by the acquisition of...Show More
Illumina, a global leader in DNA sequencing and array-based technologies, has reported a 2% decrease in revenue for the fiscal year 2023, amounting to $4.5 billion compared to $4.6 billion in the previous year. The decline was attributed primarily to reduced sales in sequencing consumables and instruments, though partially offset by increased service and other revenue. Gross profit margin also fell to 60.9% from 64.8% in 2022, influenced by lower fixed cost leverage and reduced instrument margins following the NovaSeq X launch. Operating loss improved to $(1.1) billion in 2023 from $(4.2) billion in 2022, with a significant reduction in operating expenses, including a decrease in goodwill and intangible impairment charges. The company's effective tax rate was (3.9)% in 2023. Illumina's business development has been marked by the acquisition of GRAIL, a healthcare company specializing in early cancer detection, although the acquisition is currently under legal scrutiny with a divestiture planned for 2024. Illumina operates in two segments: Core Illumina and GRAIL, with the former expected to maintain flat revenue in 2024. The company's financial performance has been influenced by macroeconomic factors, competitive challenges, and geopolitical tensions. Despite these challenges, Illumina is committed to cost reduction initiatives to improve margins and invest in high-growth areas.
DNA測序和基於陣列技術的全球領先企業Illumina報告稱,在2023財年其營業收入下降了2%,爲450億美元,相較於上一年的460億美元有所減少。這種下降主要歸因於測序耗材和儀器的銷售減少,部分抵消了服務和其他收入的增加。毛利率也從2022年的64.8%下降到了60.9%,受到固定成本槓桿的降低和NovaSeq X推出後儀器利潤降低的影響。營業虧損從2022年的42億美元減少到了2023年的11億美元,企業的營業費用顯著降低,包括商譽和無形資產減值損失的減少。該公司的有效稅率爲-3.9%。Illumina的業務發展標誌着GRAIL公司的收購,該公司專門從事早期癌症檢測,儘管該收購目前正在進...展開全部
DNA測序和基於陣列技術的全球領先企業Illumina報告稱,在2023財年其營業收入下降了2%,爲450億美元,相較於上一年的460億美元有所減少。這種下降主要歸因於測序耗材和儀器的銷售減少,部分抵消了服務和其他收入的增加。毛利率也從2022年的64.8%下降到了60.9%,受到固定成本槓桿的降低和NovaSeq X推出後儀器利潤降低的影響。營業虧損從2022年的42億美元減少到了2023年的11億美元,企業的營業費用顯著降低,包括商譽和無形資產減值損失的減少。該公司的有效稅率爲-3.9%。Illumina的業務發展標誌着GRAIL公司的收購,該公司專門從事早期癌症檢測,儘管該收購目前正在進行法律審查,計劃在2024年進行剝離。Illumina分爲兩個業務板塊:核心Illumina和GRAIL,前者預計在2024年保持收入不變。儘管面臨宏觀經濟因素、競爭壓力和地緣政治緊張局勢的挑戰,但Illumina致力於成本削減舉措,以提高利潤率並投資於高增長領域。
有用
沒用
譯文內容由第三人軟體翻譯。
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
資訊熱榜
更新時間